Dynamic Technology Lab Private Ltd purchased a new position in shares of Edwards Lifesciences Corp (NYSE:EW) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 5,600 shares of the medical research company’s stock, valued at approximately $782,000.
Several other large investors also recently bought and sold shares of EW. Optimum Investment Advisors acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $110,000. IHT Wealth Management LLC grew its stake in Edwards Lifesciences by 84.6% in the 1st quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock valued at $126,000 after acquiring an additional 427 shares during the last quarter. Well Done LLC acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $152,000. Peregrine Asset Advisers Inc. acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $204,000. Finally, Cetera Advisor Networks LLC acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $206,000. 80.89% of the stock is currently owned by institutional investors and hedge funds.
In related news, VP Huimin Wang sold 3,800 shares of the firm’s stock in a transaction that occurred on Friday, May 4th. The shares were sold at an average price of $131.93, for a total value of $501,334.00. Following the transaction, the vice president now owns 85,016 shares in the company, valued at $11,216,160.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael A. Mussallem sold 32,800 shares of the firm’s stock in a transaction that occurred on Monday, April 30th. The shares were sold at an average price of $128.46, for a total transaction of $4,213,488.00. Following the completion of the transaction, the chief executive officer now owns 74,131 shares in the company, valued at approximately $9,522,868.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 230,582 shares of company stock worth $31,499,888. Insiders own 1.84% of the company’s stock.
Shares of Edwards Lifesciences opened at $144.76 on Thursday, Marketbeat.com reports. The stock has a market cap of $31.61 billion, a PE ratio of 38.09, a P/E/G ratio of 2.20 and a beta of 0.65. Edwards Lifesciences Corp has a 1-year low of $100.20 and a 1-year high of $155.22. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.63 and a current ratio of 2.07.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, April 24th. The medical research company reported $1.22 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.11. The business had revenue of $938.00 million for the quarter, compared to analyst estimates of $936.69 million. Edwards Lifesciences had a net margin of 17.36% and a return on equity of 28.60%. The company’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.94 EPS. analysts forecast that Edwards Lifesciences Corp will post 4.63 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on the stock. ValuEngine raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Monday, May 7th. Sanford C. Bernstein assumed coverage on shares of Edwards Lifesciences in a research note on Wednesday. They issued a “market perform” rating and a $165.00 price objective on the stock. Raymond James assumed coverage on shares of Edwards Lifesciences in a research note on Thursday, May 31st. They issued an “outperform” rating and a $152.00 price objective on the stock. Northland Securities cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 25th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $140.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, April 25th. Six analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Edwards Lifesciences currently has a consensus rating of “Buy” and a consensus target price of $150.00.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.